On February 7, Merck KGaA, a leading pharmaceutical and chemical company, successfully completed its €1.05bn rights issue combined with private placements with institutional investors.
The capital increase is to partly finance the recent €10.6bn acquisition of Swiss pharmaceutical company Serono S.A., which will strengthen Merck´s pharmaceuticals business and result in Merck becoming a leading player in the global biologic medicines market.
BNP Paribas Corporate Finance acted as Joint Bookrunner along with Deutsche Bank, Citigroup, Goldman Sachs